Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.
复制标题
找到一种简单的方法来协调：EZH2抑制剂的临床研究和组合策略的进展综述。
DOI：
10.1186/s13148-021-01045-1
复制
发表时间：
2021-03-24
影响因子：
5.7
通讯作者：
Xue L
中科院分区：
文献类型：
--
作者：
Li C;Wang Y;Gong Y;Zhang T;Huang J;Tan Z;Xue L
ZAST同系物2抑制剂增强剂(EZH2)通过靶向EZH2，一种著名的促癌因子，因其抗癌活性而受到越来越多的关注。然而，一些淋巴瘤对EZH2具有耐药性，对于EZH2过表达的实体瘤，单独使用EZH2治疗无效。通过将这些药物与其他治疗方式安全有效地结合起来，EZH2 i的抗癌效果可能会得到改善。临床前证据表明，EZH2 i与其他治疗方法，如免疫治疗、化疗、靶向治疗和内分泌治疗相结合，具有互补或协同的抗肿瘤作用。因此，阐明联合疗法各个成分的潜在机制是其临床应用的基础。在本文中，我们总结了值得注意的临床试验和临床前研究，它们的进展，以及EZH2与不同治疗方式的联合应用，旨在为肿瘤的治疗提供新的见解。
Enhancer of zeste homolog 2 inhibitors (EZH2i) have garnered increased attention owing to their anticancer activity by targeting EZH2, a well-known cancer-promoting factor. However, some lymphomas are resistant to EZH2i, and EZH2i treatment alone is ineffective in case of EZH2-overexpressing solid tumors. The anti-cancer efficacy of EZH2i may be improved through safe and effective combinations of these drugs with other treatment modalities. Preclinical evidence indicates that combining EZH2i with other therapies, such as immunotherapy, chemotherapy, targeted therapy, and endocrine therapy, has complementary or synergistic antitumor effects. Therefore, elucidating the underlying mechanisms of the individual constituents of the combination therapies is fundamental for their clinical application. In this review, we have summarized notable clinical trials and preclinical studies using EZH2i, their progress, and combinations of EZH2i with different therapeutic modalities, aiming to provide new insights for tumor treatment.
登录
查看更多内容
影响因子：
28.2
作者：
Ennishi, Daisuke;Takata, Katsuyoshi;Steidl, Christian
通讯作者：
Steidl, Christian
影响因子：
4.8
作者：
Bai, Yunfeng;Zhang, Zhuangzhuang;Liu, Xiaoqi
通讯作者：
Liu, Xiaoqi
影响因子：
5.6
作者：
Eckschlager T;Plch J;Stiborova M;Hrabeta J
通讯作者：
Hrabeta J
影响因子：
11.4
作者：
Bracken, AP;Pasini, D;Helin, K
通讯作者：
Helin, K
影响因子：
64.8
作者：
Fillmore, Christine M.;Xu, Chunxiao;Desai, Pooja T.;Berry, Joanne M.;Rowbotham, Samuel P.;Lin, Yi-Jang;Zhang, Haikuo;Marquez, Victor E.;Hammerman, Peter S.;Wong, Kwok-Kin;Kim, Carla F.
通讯作者：
Kim, Carla F.